Innovative Drug Discovery Model
At MD Anderson, we work under the same roof as world-class physicians and researchers, providing unparalleled insights that guide each of our programs. We learn from those we treat, starting with a patient and their cancer in order to drive new therapeutics based on specific unmet needs.
To discover and develop effective new therapies, we have created state-of-the-art research platforms with industry-scale capabilities and collaborative teams of experts driven toward a singular goal: improving the lives of our patients.
Therapeutics Discovery Research Platforms
Collaborative Agreements
Our collaborative agreements with leading pharmaceutical and biotechnology companies also are critical to our mission of advancing impactful therapies. These agreements can take a variety of forms based on how best to meet the needs of our patients.
Strategic Alliances
By aligning with leading biopharmaceutical companies and strategic investors, we are able to combine the unique infrastructure and drug development capabilities of Therapeutics Discovery with the novel therapeutics and expertise of our collaborators to accelerate new therapies to benefit patients.
-
Astellas
Agreement to research and develop new treatments for patients with acute myeloid leukemia
-
Boehringer Ingelheim
Multi-year collaboration to rapidly advance therapies for multiple cancer types
-
Denali Therapeutics
Research collaboration with NDC to develop novel therapies for Alzheimer’s and other neurodegenerative diseases
-
Ionis
Research collaboration using Ionis’ antisense technology and MD Anderson's expertise to develop novel cancer therapies
-
Taiho Oncology
Collaboration to conduct preclinical development and clinical evaluation of novel medicines to treat brain metastases
-
Takeda
Exclusive license and research agreement to develop off-the-shelf CAR NK cell therapy platform
Joint Ventures
Establishing new companies allows us to advance promising medicines discovered and developed by our teams with the managerial, operational and investment expertise of our strategic partners.
-
Magnolia Neurosciences
Launched with Accelerator Life Sciences Partners to develop neuroprotective medicines based on IACS and NDC discoveries
-
Navire Pharma
Launched with BridgeBio Pharma to develop novel small-molecule inhibitors of a tyrosine-protein phosphatase SHP2
-
Vescor
Launched with Deerfield Management to discover and develop autophagy targeted therapeutics for cancer treatment
Licensing Agreements
We have licensed novel therapeutics discovered within our platforms to companies committed to advancing these medicines toward patients in need, often collaborating for ongoing development and early-stage clinical trials.
-
Artios
In-licensing agreement by Artios of small-molecule ATR inhibitor program developed by MD Anderson and ShangPharma
-
GSK
Research collaboration, license agreement to create therapeutic antibodies promoting immune system attack against cancer
-
Ipsen
Global licensing and joint development agreement for pre-clinical oncology drug candidate discovered by IACS